Formation Bio

Founding and History

Formation Bio was founded in 2016 (originally as TrialSpark) by Ben Liu and Linhao Zhang to address inefficiencies in clinical development. Initially focused on clinical trial technology, the company expanded into acquiring and developing clinical-stage drug candidates. In 2023, the company rebranded as Formation Bio to reflect its evolution into a fully integrated, tech-enabled pharmaceutical organization.

Therapy Areas and Focus

Formation Bio is therapeutically agnostic and prioritizes areas where its development platform can accelerate progress. Its portfolio includes programs in:

• Immunology and Inflammation
• Autoimmune and Gastrointestinal Diseases
• Musculoskeletal Degeneration
• Dermatology (including partnered assets)

The company’s strategy centers on in-licensing or acquiring clinical-phase assets and advancing them efficiently through development.

Technology Platforms and Modalities

Formation Bio operates as a “pharma of the future,” leveraging a proprietary, AI-native development engine that combines software, machine learning, and optimized operational systems. The platform spans trial design, data operations, regulatory documentation, and clinical execution. Modalities under development include small molecules, biologics, and monoclonal antibodies.

Key Personnel

• Ben Liu – Chief Executive Officer and Co-Founder
• Linhao Zhang – Co-Founder
• Dan Neil, PhD – Chief Technology Officer
• Gavin Corcoran, MD – Chief Development Officer
• Lou Brenner, MD – Chief Medical Officer
• James Leslie – Chief Financial Officer
• David Steinberg – Chief Business Officer

Strategic Partnerships

Formation Bio collaborates with leading pharmaceutical and technology organizations, including a high-profile partnership with Sanofi and OpenAI to build specialized AI models for drug development. The company also pursues licensing deals for clinical assets and maintains relationships with major venture investors and research institutions.

FAQ Section

What is Formation Bio’s core science and biotech platform?

Formation Bio’s platform centers on AI-enabled drug development. Rather than discovering new molecules, the company acquires clinical-stage programs and applies its technology engine to advance them more rapidly and cost-effectively.

What diseases and therapeutic areas does Formation Bio focus on?

The company develops treatments across multiple therapeutic areas, including immunology, inflammation, autoimmune disease, gastrointestinal conditions, musculoskeletal disorders, and dermatology.

What programs and products are in Formation Bio’s clinical pipeline?

Formation Bio’s disclosed pipeline includes:

• LNK01006 – TYK2 inhibitor (Phase I)
• RVW101 – Anti-CD226 monoclonal antibody (Phase I)
• Sprifermin – Recombinant FGF18 for knee osteoarthritis (Phase II)
• Gusacitinib – SYK/JAK inhibitor for chronic hand eczema (Phase III; partnered)

What is the latest company news and recent events?

Recent developments include significant financing rounds, leadership expansion, and strategic collaborations designed to scale the company’s AI-native development model and expand its clinical pipeline.

What clinical trial data and results has Formation Bio announced?

Clinical programs are advancing through Phases I–III, with updates shared on trial initiation, patient enrollment, mechanism validation, and progression milestones.

What are Formation Bio’s regulatory interactions and upcoming milestones?

Formation Bio’s regulatory priorities include advancing early- and mid-stage programs through IND-relevant development, supporting late-stage programs with partners, and expanding its technology platform to streamline regulatory submissions.

Who comprises Formation Bio’s leadership team and what is their track record?

The leadership combines expertise in AI, biopharmaceutical development, clinical strategy, and company scaling. Collectively, team members and advisors have contributed to dozens of approved therapies and hundreds of clinical trials across major therapeutic categories.